Achilles Therapeutics
Seedtable Score
60
Startups
3
Funding Rounds
6
Investors
$201m
Money raised
Overview
Achilles Therapeutics, based in London, shows strong potential in the competitive field of cancer treatment. The company focuses on next-generation, patient-specific immunotherapies, developing treatments tailored to individual patients. This personalized approach aims to increase effectiveness and reduce side effects compared to standard therapies. Supported by investors such as AlbionVC and Forbion Capital Partners, Achilles is well-positioned to advance medical technology and meet the growing demand for innovative cancer treatments. If they demonstrate significant clinical success, their unique offering could make a substantial market impact.
- Website: https://achillestx.com
- Business model: b2b
- Company size: 101 - 251 employees
- Headquarters: London, UK
- Founded: 2016
- Social accounts: Twitter Linkedin
Unlock Complete Company Intelligence
Access comprehensive data and insights available only to Seedtable members
Financial Details
- • Complete funding history and valuations
- • Revenue estimates and financial metrics
- • Investment round details and terms
People & Contacts
- • Complete leadership team profiles
- • Contact information and email addresses
- • Board members and advisors
Market Intelligence
- • Competitive landscape analysis
- • Market position and growth metrics
- • Industry benchmarking data
Premium Tools
- • Export data and generate reports
- • Save companies to custom watchlists
- • API access for data integration
Join 10,000+ Professionals
Trusted by investors, founders, and analysts worldwide
Access detailed insights on 71,000+ companies worldwide
Investors (6)
Funding
Funding series
Funding Series Analysis
The company Achilles Therapeutics has raised a total of $201m in funding over 3 rounds.
Key Insights:
- Series C: $68m
- Series B: $116m
- Seed: $17m
Achilles Therapeutics Series B (2019, $116M)
$116m
Achilles Therapeutics Series C (2020, $68M)
$68m
Achilles Therapeutics Seed (2016, $17M)
$17m